HROW

Dopo l'orario di chiusura: 25.30 -0.75 -2.88%

Harrow Inc (HROW)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché HROW Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Harrow Inc Stock (HROW) Company Profile

Healthcare (1161)

615.733.4731

102 WOODMONT BLVD, NASHVILLE, CA

Prossima data di guadagno

Ultimi documenti SEC

HROW's Discussions on Twitter

Confronta HROW con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HROW Harrow Inc	26.05	890.64M	154.15M	-33.58M	-20.74M	-0.96
ZTS Zoetis Inc	163.50	72.50B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	14.98	47.08B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.16	45.99B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.29	17.52B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	312.26	13.78B	2.76B	1.11B	898.10M	22.77

Harrow Inc Stock (HROW) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-02-06	Iniziato	H.C. Wainwright	Buy
2024-12-04	Reiterato	B. Riley Securities	Buy
2024-04-11	Iniziato	Craig Hallum	Buy
2022-09-08	Ripresa	B. Riley Securities	Buy
2021-10-14	Ripresa	B. Riley Securities	Buy
2021-09-24	Iniziato	Aegis Capital	Buy
2021-07-02	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Harrow Inc Borsa (HROW) Ultime notizie

Harrow Inc Azioni (HROW) Dati Finanziari

Harrow Inc (HROW)

Harrow Inc Stock (HROW) Company Profile

Confronta HROW con altri titoli

Harrow Inc Stock (HROW) Upgrades & Downgrades

Harrow Inc Borsa (HROW) Ultime notizie

Where Harrow Stands With Analysts - Benzinga

B. Riley Adjusts Price Target on Harrow to $65 From $69, Maintains Buy Rating - MarketScreener

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance

Harrow Health Reports Strong 2024 Financial Performance - TipRanks

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha

Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

Harrow: Q4 Earnings Snapshot - The Advocate

Harrow Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Joplin Globe

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 - Business Wire

Harrow Inc. sees $150k stock sale by Opaleye Management - Investing.com

Harrow sees shares increase following drug approval - Nashville Post

Craig-Hallum Reaffirms Their Buy Rating on Harrow Health (HROW) - The Globe and Mail

CMS approves separate reimbursement for Harrow’s TRIESENCE - Investing.com

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire

TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan

Harrow Inc (HROW) Shares Up 1.14% on Mar 22 - GuruFocus

Opaleye management sells $148,200 in Harrow, Inc. stock - Investing.com India

What To Expect From Harrow Inc (HROW) Q4 2024 Earnings - GuruFocus

Opaleye Management Inc. Adjusts Stake in Harrow Inc. - GuruFocus

Bank of New York Mellon Corp Has $2.90 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World

Harrow Inc (HROW) Shares Up 2.97% on Mar 21 - GuruFocus

Opaleye management sells $148,200 in Harrow, Inc. stock By Investing.com - Investing.com South Africa

Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha

H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target By Investing.com - Investing.com Australia

H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target - Investing.com India

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial - GlobeNewswire Inc.

Harrow stock surges on preliminary Q4 numbers - Nashville Post

Sector Update: Health Care -March 18, 2025 at 08:49 am EDT - Marketscreener.com

Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga India

Harrow Reports Preliminary 2024 Q4 and Full-Year Financial Results, Provides 2025 Guidance and Launches New Initiative - VisionMonday.com

Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus.com

Harrow Completes Transfer of the TRIESENCE® New Drug Application - Business Wire

Harrow Reports Q4 Preliminary Revenue -- Shares Rise After Hours -March 17, 2025 at 04:30 pm EDT - Marketscreener.com

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance - Business Wire

Harrow Launches VEVYE® Access for All - Business Wire

Harrow Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga

HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More - Nasdaq

Harrow shares react modestly to FDA move | Area Stocks - Nashville Post

Harrow shares react modestly to FDA move - Nashville Post

Harrow shares react to FDA move - Nashville Post

Harrow Signs 5-Year Supply Deal for Triesence -March 11, 2025 at 08:36 am EDT - Marketscreener.com

Harrow Executes Five-Year Strategic Supply And Development Agreement For TRIESENCE - Marketscreener.com

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE® - Business Wire

Harrow Inc Azioni (HROW) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a HROW